The first patients in Europe and Israel have been dosed in a phase 2b study of Opthea’s OPT-302 for wet age-related macular degeneration, according to a press release.
OPT-302, a novel VEGF-C/D “trap” therapy, is being evaluated in combination with Lucentis (ranibizumab, Genentech) over a 6-month dosing period.
The ongoing randomized, controlled, international trial is enrolling patients at more than 50 U.S. sites, 50 European sites and six Israeli sites. A total of 351 patients with wet AMD who have not received prior treatment will be enrolled, the release said.
“The
Uncategorized